Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05995535
PHASE2

Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

Sponsor: University of Pennsylvania

View on ClinicalTrials.gov

Summary

A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after completing withdrawal.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2024-01-01

Completion Date

2026-08-31

Last Updated

2026-02-13

Healthy Volunteers

Yes

Interventions

DRUG

LFX/PGB

lofexidine tablets 0.18mg tabs pregabalin capsules 100mg and 25mg

DRUG

LFX/PLA-PGB

lofexidine tablets 0.18mg tabs pregabalin capsules 0mg

Locations (2)

Mountain Manor Treatment Center

Baltimore, Maryland, United States

University of Pennsylvania, Treatment Research Center

Philadelphia, Pennsylvania, United States